Rubius Therapeutics Inc. (RUBY) 20 Days SMA touches -42.03%: The odds favor the bear


A new trading day began on September 22, 2022, with Rubius Therapeutics Inc. (NASDAQ: RUBY) stock priced at $0.488, down -7.21% from the previous day of trading. During the day, the shares moved up to $0.51 and dropped to $0.4407 before settling in for the closing price of $0.49. RUBY’s price has ranged from $0.47 to $19.82 over the past 52 weeks.

Top 5 Tech Stocks Every Investor Should Buy Right Now

While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.

Sign up here to get your free report now.


Meanwhile, its annual earnings per share averaged -7.40%. With a float of $84.39 million, this company’s outstanding shares have now reached $90.26 million.

Considering the fact that the conglomerate employs 213 people, you should pay attention to its efficiency factor.

Rubius Therapeutics Inc. (RUBY) Insider Activity

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Rubius Therapeutics Inc. is 5.20%, while institutional ownership is 87.30%. The most recent insider transaction that took place on Aug 10, was worth 4,590. In this transaction Chief Operating Officer of this company sold 5,737 shares at a rate of $0.80, taking the stock ownership to the 6,763 shares. Before that another transaction happened on Apr 21, when Company’s Director bought 30,000 for $1.44, making the entire transaction worth $43,329. This insider now owns 4,720,012 shares in total.

Rubius Therapeutics Inc. (RUBY) Earnings and Forecasts

In its latest quarterly report, released on 6/29/2022, the company reported earnings of -$0.49 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a return on equity of -122.71. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -7.40% per share during the next fiscal year.

Rubius Therapeutics Inc. (NASDAQ: RUBY) Trading Performance Indicators

Here are Rubius Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.60.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.23, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -0.98 in one year’s time.

Technical Analysis of Rubius Therapeutics Inc. (RUBY)

Compared to the last year’s volume of 1.85 million, its volume of 2.2 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 2.31%. Additionally, its Average True Range was 0.12.

During the past 100 days, Rubius Therapeutics Inc.’s (RUBY) raw stochastic average was set at 1.03%, which indicates a significant decrease from 1.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 251.43% in the past 14 days, which was higher than the 137.58% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.7631, while its 200-day Moving Average is $3.7616. Nevertheless, the first resistance level for the watch stands at $0.4962 in the near term. At $0.5377, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5655. If the price goes on to break the first support level at $0.4269, it is likely to go to the next support level at $0.3991. Should the price break the second support level, the third support level stands at $0.3576.

Rubius Therapeutics Inc. (NASDAQ: RUBY) Key Stats

With a market capitalization of 49.85 million, the company has a total of 90,357K Shares Outstanding. Currently, annual sales are 0 K while annual income is -196,550 K. The company’s previous quarter sales were 0 K while its latest quarter income was -44,240 K.


Please enter your comment!
Please enter your name here